The Trouble with Group 3 Pulmonary Hypertension in Interstitial Lung Disease: Dilemmas in Diagnosis and the Conundrum of Treatment.
The Trouble with Group 3 Pulmonary Hypertension in Interstitial Lung Disease: Dilemmas in Diagnosis and the Conundrum of Treatment.
Chest. 2020 May 06;:
Authors: King CS, Shlobin OA
Abstract
Pulmonary hypertension due to interstitial lung disease (PH-ILD) can complicate a multitude of interstitial lung diseases including idiopathic pulmonary fibrosis, chronic hypersensitivity pneumonitis, and non-specific interstitial pneumonitis. Development of PH-ILD is associated with increased need for supplemental oxygen, reduced mobility, and decreased survival. A high index of suspicion is required to make the diagnosis given the substantial overlap in symptoms with those of interstitial lung disease without PH. Severely reduced diffusing capacity or six-minute walk test distance, prominent exertional desaturation and impaired heart rate recovery following exercise are all suggestive of the development of PH-ILD. Traditional transthoracic echocardiography (TTE) is the most commonly employed screening test for PH-ILD but it lacks sensitivity and specificity. Newer echocardiograpahic tools employing 3D assessment of the right ventricle may have a role in both prognosis and monitoring of patients with PH-ILD. Right heart catheterization remains the gold standard for confirming a diagnosis of PH-ILD. While there is little debate over the use of supplemental oxygen and diuretic therapy in the treatment of PH-ILD, treatment with pulmonary vasodilato...
Source: Chest - Category: Respiratory Medicine Authors: King CS, Shlobin OA Tags: Chest Source Type: research
More News: Cardiac Catheterization | Cardiology | Heart | Hypertension | Interstitial Lung Disease | Pulmonary Hypertension | Respiratory Medicine | Science | Sports Medicine | Study